Education
About Us
Working with TipRanks
Follow Us
Bio-Path Holdings (BPTH)
OTHER OTC:BPTH
Top Page
Bio-Path Holdings
(OTC:BPTH)
Select Model
Select Model
Rating:37Underperform
Price Target:―
Bio-Path Holdings' stock is significantly challenged by poor financial performance, characterized by no revenue and high cash burn. The technical indicators also suggest a bearish trend. However, the promising pre-clinical results offer a glimmer of hope for future prospects. The negative P/E ratio and lack of dividend yield further contribute to a low valuation score. Overall, the stock is risky, with financial sustainability being a major concern.
Bio-Path Holdings (BPTH) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$569.51K
Dividend YieldN/A
Average Volume (3M)108.74K
Price to Earnings (P/E)―
Beta (1Y)-1.40
Revenue GrowthN/A
EPS Growth88.04%
CountryUS
Employees10
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.55
Shares Outstanding8,307,892
10 Day Avg. Volume130,255
30 Day Avg. Volume108,737
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap3.32
Enterprise Value/Revenue11.97
Enterprise Value/Gross Profit-70.05
Enterprise Value/Ebitda-0.15
Forecast
1Y Price Target
$2.00Price Target Upside2757.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Bio-Path Holdings Business Overview & Revenue Model
Company DescriptionBio-Path Holdings, Inc. is a biotechnology company that develops RNAi nanoparticle drug products to treat various cancer types. The company operates within the biotechnology and pharmaceutical sectors, focusing on the development of therapeutics for cancer treatment. Its core products include pre-clinical and clinical stage candidates such as BP1001, BP1002, and BP1003, which are designed to address unmet medical needs in oncology.
How the Company Makes MoneyBio-Path Holdings makes money primarily through the development and commercialization of its proprietary drug candidates. The company's revenue model includes licensing agreements, partnerships with larger pharmaceutical firms, and potential future sales of approved drugs. Bio-Path may also receive milestone payments and royalties from these partnerships and collaborations as their drug candidates advance through clinical trials and, if successful, reach the market. Additionally, the company might engage in raising capital through stock offerings to fund its research and development efforts.
Bio-Path Holdings Earnings Call Summary
Earnings Call Date:Aug 19, 2025
(Q3-2024)
| % Change Since: |
Next Earnings Date:Nov 14, 2025
Earnings Call Sentiment Positive
The call highlighted significant advancements in clinical trials and the expansion of the DNAbilize platform into new therapeutic areas, reflecting strong progress in drug development. Despite some financial challenges, such as increased administrative expenses and a decrease in cash position, the overall outlook remains positive due to substantial progress in pipeline advancements and research publications.Q3-2024 Updates
Positive Updates
Expansion of DNAbilize Platform
Initiation of clinical development program for BP-1001-A as a treatment for obesity and related metabolic diseases, marking the first non-cancer application of DNAbilize platform.
Progress in Cancer Treatment Trials
Continued advancement of Phase I/Ib clinical trials for BP1001-A in patients with solid tumors and BP1002 in refractory relapsed AML patients.
Publication and Potential of BP1003
Publication in Biomedicines journal highlighting the therapeutic potential of BP1003 in various cancer types, including breast, ovarian, and pancreatic cancer.
Financial Improvements
Net loss decreased to $2.1 million in Q3 2024 from $3.2 million in Q3 2023, with a decrease in research and development expenses.
Rapid Enrollment in Clinical Trials
Faster than projected enrollment for the third dosing cohort of 60 mg/m² in the BP1002 trial, completed within six weeks.
Negative Updates
Increased General and Administrative Expenses
General and administrative expenses increased to $1.3 million in Q3 2024 from $1.0 million in Q3 2023, primarily due to increased legal fees and salaries.
Cash Position Decrease
Cash decreased to $0.6 million as of September 30, 2024, from $1.1 million as of December 31, 2023.
Company Guidance
In the Bio-Path Holdings Q3 2024 earnings call, the company reported a net loss of $2.1 million, or $0.70 per share, which marks an improvement from the $3.2 million loss, or $6.36 per share, in the same period last year. Research and development expenses decreased to $1.3 million from $2.3 million, attributed to reduced manufacturing costs and clinical trial expenses. General and administrative expenses rose to $1.3 million from $1.0 million, driven by increased legal fees and salaries. The company's cash reserves stood at $0.6 million as of September 30, 2024, down from $1.1 million at the end of 2023, with $7.7 million net cash used in operating activities and $7.2 million generated from financing activities over the first nine months of 2024. Bio-Path is advancing its DNAbilize platform, aiming to expand into obesity and metabolic diseases while progressing clinical trials in oncology.Bio-Path Holdings Financial Statement Overview
Summary
Bio-Path Holdings faces significant financial challenges with no revenue generation, persistent losses, and reliance on external financing. The high cash burn rate coupled with declining equity suggests substantial risks in maintaining operations without strategic shifts or new revenue streams.Income Statement
The company has not generated any revenue over the past years, which is a significant concern for sustainability. The net losses persist with no visible revenue growth, indicating potential financial instability.10
Very Negative
Balance Sheet
The company has a very low equity base with rising liabilities, leading to a deteriorating debt-to-equity ratio. The equity ratio has decreased significantly over the years, which suggests increased financial risk.20
Very Negative
Cash Flow
The operating cash flows are negative, reflecting a high burn rate without corresponding inflows from operations. Financing activities have been the primary source of cash, raising concerns about long-term viability without revenue generation.15
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 158.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -27.00K | -159.00K | -178.00K | -178.00K | -161.00K | -151.00K |
| EBITDA | -12.52M | -9.73M | -15.76M | -13.69M | -10.28M | -10.73M |
| Net Income | -12.32M | -9.89M | -16.08M | -13.84M | -10.44M | -10.86M |
Balance Sheet | ||||||
| Total Assets | 746.00K | 3.88M | 3.22M | 15.97M | 26.57M | 16.48M |
| Cash, Cash Equivalents and Short-Term Investments | 0.00 | 1.17M | 1.05M | 10.38M | 23.77M | 13.76M |
| Total Debt | 479.00K | 83.00K | 113.00K | 221.00K | 235.00K | 330.00K |
| Total Liabilities | 7.90M | 3.73M | 2.78M | 1.80M | 1.11M | 1.41M |
| Stockholders Equity | -7.16M | 154.00K | 441.00K | 14.17M | 25.46M | 15.07M |
Cash Flow | ||||||
| Free Cash Flow | -7.91M | -10.57M | -11.54M | -15.12M | -9.99M | -10.96M |
| Operating Cash Flow | -7.91M | -10.57M | -11.54M | -15.10M | -9.92M | -10.96M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -21.00K | -70.00K | 0.00 |
| Financing Cash Flow | 3.90M | 10.70M | 2.20M | 1.73M | 20.01M | 4.29M |
Bio-Path Holdings Technical Analysis
Negative
0.07
Price Trends
0.11
Negative
0.15
Negative
0.32
Negative
Market Momentum
-0.02
Negative
39.39
Neutral
61.51
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BPTH, the sentiment is Negative. The current price of 0.07 is below the 20-day moving average (MA) of 0.08, below the 50-day MA of 0.11, and below the 200-day MA of 0.32, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 39.39 is Neutral, neither overbought nor oversold. The STOCH value of 61.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BPTH.
Bio-Path Holdings Risk Analysis
Bio-Path Holdings disclosed 47 risk factors in its most recent earnings report. Bio-Path Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Bio-Path Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $2.50M | ― | -19.18% | ― | -27.81% | ― | |
44 Neutral | $9.61M | -0.12 | -377.46% | ― | -43.77% | 55.78% | |
37 Underperform | $569.51K | ― | -3325.71% | ― | ― | 88.04% | |
37 Underperform | $3.48M | -0.01 | ― | ― | -19.81% | 93.32% | |
33 Underperform | $5.24M | >-0.01 | -610.69% | ― | -9.34% | 93.84% | |
28 Underperform | $2.20M | ― | ― | ― | ― | 85.35% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
BPTH
Bio-Path Holdings
0.07
-0.84
-92.31%
BDRX
Biodexa Pharmaceuticals
6.35
-64.20
-91.00%
QCLS
Q/C Technologies
―
―
―
SLRX
Salarius Pharmaceuticals
3.81
-17.79
-82.36%
SCNI
Scinai Immunotherapeutics
1.32
-2.13
-61.74%
OGEN
Oragenics
1.27
-10.17
-88.90%
Bio-Path Holdings Corporate Events
Product-Related AnnouncementsBusiness Operations and Strategy
Bio-Path Holdings Reports Promising Pre-Clinical Results
Positive
Mar 19, 2025
On March 18, 2025, Bio-Path Holdings announced promising pre-clinical results for BP1001-A, indicating its potential as a treatment for obesity in Type 2 diabetes patients. The studies showed that BP1001-A attenuated fatty acid-induced insulin resistance and restored insulin sensitivity in muscle progenitor and skeletal muscle fiber cell models. This progress suggests a new application for BP1001-A beyond current weight loss drugs, potentially offering a novel therapeutic option for reducing glucose levels in patients with Type 2 diabetes. Bio-Path plans to advance these studies and file for regulatory designations to accelerate approval, with a final pre-clinical mouse model study expected in the first half of 2025 and an IND filing by year-end.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.